Curated News
By: NewsRamp Editorial Staff
September 15, 2025
Onassis Launches $75M Reg A+ Funding for Longevity Breakthroughs
TLDR
- Onassis Holdings' $75 million Regulation A+ financing offers investors early access to biotech longevity innovations through Dalmore Group's established market network.
- Onassis Holdings partners with Dalmore Group to execute a Regulation A+ financing round, enabling public investment in epigenetic rejuvenation technologies up to $75 million annually.
- This funding supports Onassis Holdings' development of epigenetic therapies that rejuvenate aging cells, potentially extending healthy human lifespan and improving quality of life.
- Onassis Holdings leverages patented protein technology through subsidiary Ananda Labs to reverse cellular aging while preserving cell identity through epigenetic reprogramming.
Impact - Why it Matters
This development matters because it democratizes investment access to cutting-edge longevity biotechnology that could fundamentally transform healthcare and human lifespan. Onassis Holdings' epigenetic reprogramming technology represents a frontier in anti-aging science, potentially addressing age-related diseases that affect millions worldwide. The Regulation A+ offering allows everyday investors to participate in a sector typically reserved for venture capital and institutional money, while the company's research into cellular rejuvenation could lead to breakthrough therapies for conditions like Alzheimer's, cardiovascular disease, and other age-related disorders. As global populations age, advancements in longevity technology become increasingly critical for healthcare systems and quality of life.
Summary
Onassis Holdings (OTC: ONSS), a biotech-focused holding company specializing in longevity and rejuvenation technologies through epigenetic reprogramming, has announced a major Regulation A+ financing initiative in partnership with Dalmore Group. This strategic move allows the company to raise up to $75 million annually from public investors, leveraging Dalmore's extensive experience with over 270 Reg A+ issuers since 2021 and their 16-year track record in the financial markets. The partnership provides Onassis with comprehensive support including marketing, PR services, marketplace syndication, and secondary trading solutions, positioning the company for accelerated growth in the cutting-edge field of cellular rejuvenation.
The company's innovative approach centers around its subsidiary Ananda Labs, which is developing groundbreaking therapies using patented proteins designed to rejuvenate elderly cells while preserving their distinct properties. This technology represents a significant advancement in the longevity sector, potentially addressing age-related diseases and extending healthy human lifespan. The financing round, facilitated through the InvestorWire platform and its parent company IBN (InvestorBrandNetwork), offers public investors unprecedented access to this emerging biotechnology opportunity that was previously limited to institutional and accredited investors.
InvestorWire, as part of the Dynamic Brand Portfolio at IBN, provides sophisticated communications solutions including wire-grade press release syndication, article distribution to over 5,000 outlets, enhanced press release services, and extensive social media reach to millions of followers. This comprehensive distribution network ensures that Onassis Holdings' groundbreaking work in epigenetic reprogramming and cellular rejuvenation reaches a broad audience of investors, journalists, and the general public, potentially transforming how we approach aging and age-related health challenges.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onassis Launches $75M Reg A+ Funding for Longevity Breakthroughs
